Sahney A, et al. - In patients with hepatic parkinsonism, researchers examined the effectiveness and safety of bromocriptine, a dopaminergic agent. Study participants were randomized to receive placebo or bromocriptine for 12 weeks. Investigators observed that 50 (4.9%) of 1,016 cirrhotic patients had hepatic parkinsonism. Bromocriptine therapy for 12 weeks improved rigidity, tremors, bradykinesia, and gait vs placebo, with complete and partial response in 7 patients vs no patients and 12 patients vs 1 patient, respectively.